In this article, we will delve into the exciting world of TFAP2C, exploring its various facets and its influence in different areas. From its impact on society to its implications on popular culture, TFAP2C has sparked the interest of experts and fans alike. Through a comprehensive analysis, we will examine its evolution over time and its relevance today. In addition, we will discover the perspectives of experts in the field, who will offer us a deeper insight into TFAP2C and its implications. This article seeks to provide a complete and enriching vision of TFAP2C, inviting readers to reflect and delve deeper into this fascinating topic.
Transcription factor AP-2 gamma is involved in early development, specifically morphogenesis - the formation of shape. AP2-gamma can regulate gene transcription by interacting with viral and cellular enhancing components and binding to the sequence 5'-GCCNNNGGC-3’. AP2-gamma activates genes that are important for placenta development and retinoic acid-mediated differentiation of the eyes, face, body wall, limbs, and neural tube. AP2-gamma also suppresses genes such as MYC and C/EBP alpha. It also represses CD44 expression, which is a cell marker for some breast and prostate cancers. Mutations of this transcription factor can lead to poorly developed placenta and tissues. A mutated AP2-gamma gene is known to cause branchiooculofacial syndrome (BOFS), which is a disease characterized by face and neck abnormalities, such as cleft lip or anophthalmia – lack of eyeballs, that have developed prior to birth. Complete knockout of the TAP2C gene that encoded AP-2 gamma leads to placenta malformation and embryonic/fetal death.
Auman, H. J., T. Nottoli, O. Lakiza, Q. Winger, S. Donaldson, and T. Williams. "Transcription Factor AP-2gamma Is Essential in the Extra-embryonic Lineages for Early Postimplantation Development." National Center for Biotechnology Information. U.S. National Library of Medicine, June 2002. Web. 15 Apr. 2014.
Bogachek, M. V., and R. J. Weigel. "TFAP2C (transcription Factor AP-2 Gamma (activating Enhancer Binding Protein 2 Gamma))." TFAP2C (transcription Factor AP-2 Gamma(activating Enhancer Binding Protein 2 Gamma)). Oct. 2013. Web. 15 Apr. 2014.
"Branchio-oculo-facial Syndrome." Genetics Home Reference. U.S. National Library of Medicine, 7 Apr. 2014. Web. 15 Apr. 2014.
"Genes and Mapped Phenotypes." National Center for Biotechnology Information. U.S. National Library of Medicine, 12 Apr. 2014. Web. 15 Apr. 2014.
"Transcription Factor AP-2 Gamma - TFAP2C - Homo sapiens (Human)." Transcription Factor AP-2 Gamma - TFAP2C - Homo sapiens (Human). UniProtKB, 19 Mar. 2014. Web. 15 Apr. 2014.
Zhao C, Yasui K, Lee CJ, et al. (2003). "Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis". Cancer. 98 (1): 18–23. doi:10.1002/cncr.11482. PMID12833450. S2CID41092143.
Friedrichs N, Steiner S, Buettner R, Knoepfle G (2007). "Immunohistochemical expression patterns of AP2alpha and AP2gamma in the developing fetal human breast". Histopathology. 51 (6): 814–23. doi:10.1111/j.1365-2559.2007.02887.x. PMID18042070. S2CID85866319.